• About Us
    • Who We Are
    • Our History
    • Mission & Values
    • Why Choose Jost
  • Products
    • Ammonium
    • Calcium
    • Copper
    • Iron
    • Magnesium
    • Manganese
    • Potassium
    • Sodium
    • Strontium
    • Zinc
    • Ultra Pure Minerals (Low Heavy Metals)
    • Infant Pure (Low Chlorate Minerals)
    • Pharma Pure
    • JOSTCOTE® Microencapsulated
    • New Products
    • Custom Products
  • Our Expertise
    • cGMP Manufacturing
    • Quality
    • Research & Development
    • Customer Service
  • Markets
    • Nutritional
    • Pharmaceutical / Biotech
    • Specialty
  • Media
    • Library
    • News
    • Events
    • Videos
  • Technical Info
    • Technical Resources
    • Links
  • Contact Us
    • Sales & Customer Service
    • Our Locations
  • Careers
Jost Chemical Co.
  • FAQ
  • Download Catalog
  • 314-428-4300
  • About Us
    • Who We Are
    • Our History
    • Mission & Values
    • Why Choose Jost
  • Products
    • Ammonium
    • Calcium
    • Copper
    • Iron
    • Magnesium
    • Manganese
    • Potassium
    • Sodium
    • Strontium
    • Zinc
    • Ultra Pure Minerals (Low Heavy Metals)
    • Infant Pure (Low Chlorate Minerals)
    • Pharma Pure
    • JOSTCOTE® Microencapsulated
    • New Products
    • Custom Products
  • Our Expertise
    • cGMP Manufacturing
    • Quality
    • Research & Development
    • Customer Service
  • Markets
    • Nutritional
    • Pharmaceutical / Biotech
    • Specialty
  • Media
    • Library
    • News
    • Events
    • Videos
  • Technical Info
    • Technical Resources
    • Links
  • Contact Us
    • Sales & Customer Service
    • Our Locations
  • Careers
Home › Related Articles › Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization.
Nanomedicine. 2019 Jan

Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization.

Abstract:

Corneal neovascularization (CNV) leads to the loss of corneal transparency and vision impairment, and can ultimately cause blindness. Topical corticosteroids are the first line treatment for suppressing CNV, but poor ocular bioavailability and rapid clearance of eye drops makes frequent administration necessary. Patient compliance with frequent eye drop application regimens is poor. We developed biodegradable nanoparticles (NP) loaded with dexamethasone sodium phosphate (DSP) using zinc ion bridging, DSP-Zn-NP, with dense coatings of poly(ethylene glycol) (PEG). DSP-Zn-NP were safe and capable of providing sustained delivery of DSP to the front of the eye following subconjunctival (SCT) administration in rats. We reported that a single SCT administration of DSP-Zn-NP prevented suture-induced CNV in rats for two weeks. In contrast, the eyes receiving SCT administration of either saline or DSP solution developed extensive CNV in less than 1 week. SCT administration of DSP-Zn-NP could be an effective strategy in preventing and treating CNV.

PMID 30677499  /  Wang B, Tang Y, Oh Y, Lamb NW, Xia S, Ding Z, Chen B, Suarez MJ, Meng T, Kulkarni V, Eberhart CG, Ensign LM, Stark WJ, Hanes J, Xu Q

Related Products
  • Library
  • News
    • Company News
    • Product Development
    • Industry News
    • Awards
  • Events
  • Videos

Learn about new Jost products and events.
subscribe

  • Who We Are
  • Products
  • Documents
  • News
  • Contact
  • Careers
  • Spanish
  • German
  • French

Follow Us

  • linkedin
  • facebook

Jost Chemical Co.
(The Americas and Asia)
8150 Lackland
St. Louis, MO 63114
Tel: +1 314 428 4300
Fax: +1 314 428 4366
customer.service@jostchemical.comcustomer.service@jostchemical.com

Jost Chemical Poland sp. z o.o
(Europe, Middle East and Africa)
ul. gen. Kazimierza Pułaskiego 7
64-000 Kościan, Poland
Tel: +48 65 322 69 00
Fax: +48 65 322 69 06
customer.service@jostchemical.comcustserv@jostchemical.com

Sitemap     Cookies     Terms of Use

Copyright © 1995–2025 Jost Chemical Co. All rights reserved.